Hepatology Research

Article	Citations
Factors associated with portopulmonary hypertension	137
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	133
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	129
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	98
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies	76
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	59
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	52
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	51
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	44
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	40
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	36
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	36
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	35
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	34
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	33
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	31
The change from NAFLD to MAFLD expands fatty liver information flow	29
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	29
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	27
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	26
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	26
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	25
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	25
Issue Information	23
Issue Information	23

Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	21
Issue Information	21
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	21
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	20
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	19
Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	19
	19
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	18
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	18
	17
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	17
Chronic liver disease questionnaire to manage patients with chronic liver diseases	17
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	17
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	16
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX9	16
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	16
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	15
Issue Information	15
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	15
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	15
	14
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	14
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	14
Measurement of spleen length and two‐dimensional spleen index is comparable to spleen volumetry by computed tomography for predicting esophageal varices	14
Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures	14
	14
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	14
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	14
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	13
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	13
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation	13
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	13
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	13
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	13
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	13
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	13
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	13
	13
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	12
Cost‐effectiveness of hepatitis E virus vaccination strategy	12
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	12
	12
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	12
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	12
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	11
	11
	11
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	11
	11
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	10

The role of the nervous system in liver diseases	10
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	10
Issue Information	10
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	10
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	10
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	9
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	9
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	9
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	9
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	9
Issue Information	9
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	9
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	8
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	8
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	8
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	8
	8
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	8
Erratum	8
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	8
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	8
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	8
Issue Information	8
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	8
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	8
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	8
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	8
Evaluating the liver function of patients with hepatocellular carcinoma	7
	7
	7
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	7
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	7
Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept	7
Issue Information	7
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	7
Metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?	7
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	7
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	7
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	7
Acknowledgment	6
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	6
Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	6
Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct‐acting antivirals	6
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	6
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	6
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	6
Clinical benefits of partial splenic embolization for cancer patients	6
Novel strategies for the early diagnosis of hepatitis B virus reactivation	6
Acknowledgments	6
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	6
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	6
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoemboliz	6
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	6
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	6
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	6
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	6
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	6
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	6
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	6
Issue Information	6
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	6
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	6
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	6
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	6
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	6
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study	5
Issue Information	5
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma	5
Cachexia is an independent predictor of mortality in patients with cirrhosis	5
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	5
Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma	5
	5
Issue Information	5
Issue Information	5
	5
A classification model for resectability in hepatocellular carcinoma patients	5
Developing a feasible classification model for surgical hepatocellular carcinoma: More questions than answers	5
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	5
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	5

An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images	5
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	5
Exosomal circCMTM3 promotes the pathogenesis of hepatocellular carcinoma via angiogenesis	5
Corrigendum	5
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	5
Issue Information	5
High serum gamma‐glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma	5
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy	5
Acknowledgment	5
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease	5
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	4
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical	4
	4
Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection	4
Issue Information	4
	4
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients	4
Fulminant hepatitis in a hepatitis B surface antigen‐positive patient with adult T‐cell leukemia‐lymphoma after mogamulizumab monotherapy	4
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in healt	4
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma	4
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	4
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	4
Liver imaging reporting and data with perfluorobutane microbubbles—Is there hope?	4
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study	4
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	4
The promise of radiotherapy for hepatocellular carcinoma	4
Issue Information	4
Identification of reversed portal flow on 4DCT and of factors contributing to reversed portal flow in patients with liver cirrhosis and portosystemic shunt before interventional radiology procedures	4
Defining advanced lymph node metastasis in intrahepatic cholangiocarcinoma: A multicenter study	4
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide seq	4
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease	4
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study	4
Real‐world trends in acute viral hepatitis in Japan: A nationwide questionnaire‐based survey	4
	4
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice	4
Serum pro‐inflammatory cytokine interleukin‐6 level is predictive of further decompensation and mortality in liver cirrhosis	4
Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic k	4
Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment‐naïve patients with chronic hepatitis B following entecavir therapy	4
	3
MET amplification as a potential therapeutic target against hepatocellular carcinoma	3
Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan	3
Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia	3
Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: A Mendelian randomization study	3
Correction to “Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression”	3
Issue Information	3
Immunoglobulin G4 (IgG4)‐related autoimmune hepatitis and IgG4‐hepatopathy: A histopathological and clinical perspective	3
Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus	3
Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis	3
Elevated serum tyrosine concentration is associated with a poor prognosis among patients with liver cirrhosis	3
What we know and need to know about Fontan‐associated liver disease	3
Corrigendum	3
	3
Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis	3
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity	3
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma	3
Apparent diffusion coefficient in intrahepatic cholangiocarcinoma diffusion‐weighted magnetic resonance imaging noninvasively predicts Ki‐67 expression	3
Algorithm of ascites management for liver cirrhosis in the tolvaptan era: Paradigm shift treatment improves the outcomes of cirrhotic patients?	3
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	3
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	3
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study	3
Involvement of the ADAMTS13–von Willebrand factor axis in acute kidney injury in mice with liver cirrhosis	3
Issue Information	3
Makuuchi's criteria for liver resection in the modern era of functional liver remnant volume evaluation	3
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab	3
Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta‐analysis	3
Issue Information	3
Significance of a multidisciplinary approach to congenital extrahepatic portosystemic shunt: A changing paradigm for the treatment	3
Impact of albumin–lymphocyte–platelet–C‐reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2–related factor 2	3
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	3
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	3
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey	3
Galectin‐3 in biliary atresia and other pediatric cholestatic liver diseases	3
	3
	2
Noninvasive graft monitoring using donor‐derived cell‐free DNA in Japanese liver transplantation	2
Aspartate aminotransferase‐to‐platelet ratio index outperforms Fibrosis‐4 in 2843 Korean patients with metabolic dysfunction‐associated steatotic liver disease	2
The ratio of serum des‐gamma‐carboxy prothrombin to tumor volume as a new biomarker for early recurrence of resected hepatocellular carcinoma	2
Multiparametric renal function assessment in cirrhotic patients shows high prevalence of medically actionable changes in multiple modules	2
Can microRNA‐96‐5p serve as a therapeutic molecule in the near future?	2
Issue Information	2
Proximal splenic artery embolization for treatment of refractory ascites, a single‐center experience	2
Clinical association between intraoperative indocyanine green fluorescence imaging pattern, preoperative Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging findings, and histological differentiation in h	2
Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma	2
Genetic alteration of SLCO1B3 defines constitutional indocyanine green excretory defect in patients who underwent hepatectomy	2
Hepatic steatosis and skeletal muscle alterations during the COVID‐19 lockdown in a cohort of patients with chronic liver disease in Japan	2
Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver disease	2
A case of A20 haploinsufficiency complicated by autoimmune hepatitis	2
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials	2
Unexpected hepatitis B virus transmission after liver transplant from nucleic acid testing‐ and serology‐negative liver donors who are hepatitis C viremic	2
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multi	2
Efficacy of laparoscopic liver resection for small hepatocellular carcinoma located in the posterosuperior segments: A multi‐institutional study using propensity score matching by the Kyushu Study Gro	2
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	2
Successful pediatric liver transplantation case with a positive SARS‐CoV‐2 test at the time of transplant	2
The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child–Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma	2
Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection	2